Crude Oil Edges Higher; Phillips 66 Posts Wider-Than-Expected Loss
Dow Falls 200 Points; Alphabet Posts Upbeat Q1 Results
12 Health Care Stocks Moving In Friday's Pre-Market Session
Lexaria Announces $2 Million Registered Direct Offering of Common Stock
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology
10-Q: Q2 2025 Earnings Report
We Think Lexaria Bioscience (NASDAQ:LEXX) Needs To Drive Business Growth Carefully
Express News | Lexaria Bioscience Corp : Maxim Group Cuts Target Price to $6 From $12
Lexaria Bioscience Announces PK Results on DehydraTech-Tirzepatide Oral Capsules
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
Lexaria Bioscience Targets Breakthrough in Oral Diabetes Medication
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
Lexaria Bioscience Granted Two New DehydraTECH Patents
Express News | Lexaria Granted Two US Patents For The Use Of DehydraTECH In Epilepsy Treatment
Express News | Lexaria Bioscience Corp. Begins Dosing In DehydraTECH GLP-1 Rodent Distribution Study
Express News | Lexaria Completes Submission To HREC For Planned Additional Of Study Arm 5 To Evaluate DehydraTECH-Tirzepatide Formulation
Lexaria Bioscience Strengthens GLP-1 Drug Delivery Focus and Expands Patent Portfolio in 2024
Lexaria Unveils 2025 R&D Plans Focused On GLP-1: To Finalize Human Pilot Study #3, Launch Phase 1b Study In Australia, Complete Human Pilot Study #5, Conduct Fluorescent Biodistribution Study, And Run Additional Animal Studies
Lexaria Releases Annual Letter From the CEO
Lexaria Bioscience Is Maintained at Buy by HC Wainwright & Co.